We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

117 hedge funds and large institutions have $476M invested in Intra-Cellular Therapies Inc. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $4.41M | Put options by funds: $2.9M

5% more capital invested

Capital invested by funds: $454M → $476M (+$22M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 129 → 117 (-12)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

32% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 22

Holders
117
Holders Change
-12
Holders Change %
-9.3%
% of All Funds
2.91%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
34
Reduced
38
Closed
22
Calls
$4.41M
Puts
$2.9M
Net Calls
+$1.5M
Net Calls Change
-$2.71M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$51.5M
2
CCP
Clough Capital Partners
Massachusetts
+$7.95M
3
RPAM
Rhenman & Partners Asset Management
Sweden
+$6.16M
4
BB
BB Biotech
Switzerland
+$5.07M
5
SC
Samlyn Capital
New York
+$4.9M

Top Sellers

Rank Fund Capital Flow
1
TCM
TimesSquare Capital Management
New York
-$23.2M
2
Jennison Associates
Jennison Associates
New York
-$15.5M
3
Citadel Advisors
Citadel Advisors
Florida
-$6.7M
4
BIM
Bogle Investment Management
Massachusetts
-$4.23M
5
CCI
Columbus Circle Investors
-$2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$106M +$308K +21,305 +0.3%
BlackRock
2
BlackRock
New York
$58.1M +$51.5M +3,560,178 +24,047%
Vanguard Group
3
Vanguard Group
Pennsylvania
$44.6M +$2.69M +186,165 +7%
BB
4
BB Biotech
Switzerland
$31.3M +$5.07M +350,000 +22%
WA
5
Wasatch Advisors
Utah
$16.3M -$142K -9,835 -1%
HIM
6
Hillhouse Investment Management
Cayman Islands
$16.3M – – –
State Street
7
State Street
Massachusetts
$14.8M -$916K -63,271 -7%
CCP
8
Clough Capital Partners
Massachusetts
$14.6M +$7.95M +549,100 +157%
Citadel Advisors
9
Citadel Advisors
Florida
$13M -$6.7M -462,955 -37%
RPAM
10
Rhenman & Partners Asset Management
Sweden
$11.6M +$6.16M +425,664 +147%
BBA
11
Baker Bros. Advisors
New York
$9.9M – – –
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$7.85M -$482K -33,311 -6%
Deutsche Bank
13
Deutsche Bank
Germany
$7.58M +$1.21M +83,656 +22%
Morgan Stanley
14
Morgan Stanley
New York
$7.02M -$869K -60,021 -12%
Northern Trust
15
Northern Trust
Illinois
$6.71M +$90.4K +6,245 +2%
CCI
16
Columbus Circle Investors
$6.19M -$2M -138,197 -27%
SCM
17
Sarissa Capital Management
Connecticut
$5.85M – – –
Millennium Management
18
Millennium Management
New York
$5.73M -$1.94M -133,846 -28%
SC
19
Samlyn Capital
New York
$5.5M +$4.9M +338,500 New
NI
20
Numeric Investors
Massachusetts
$5.28M +$3.72M +257,291 +379%
Renaissance Technologies
21
Renaissance Technologies
New York
$4.49M +$3.99M +276,000 New
Norges Bank
22
Norges Bank
Norway
$4.44M -$108K -7,496 -3%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$4.4M +$116K +8,023 +3%
DekaBank Deutsche Girozentrale
24
DekaBank Deutsche Girozentrale
Germany
$3.89M +$3.32M +229,200 +2,292%
CS
25
Candriam SCA
Luxembourg
$3.12M +$1.09M +75,000 +64%
1
2 3 4 5

ITCI Hedge Fund Activity: Q1 2017 in Review

117 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2017, worth a combined $476M — up 4.8% from $454M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ITCI and 15 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 34 added.

The largest buyer was BlackRock, adding an estimated $51.5M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $23.2M sold.

  • 117 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2017, down from 129 in Q4 2016.
  • Funds reported $476M of Intra-Cellular Therapies Inc. stock for Q1 2017, up 4.8% quarter-over-quarter.
  • 15 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2017 and 22 closed out, a net change of -7 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2017 was BlackRock, an estimated $51.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2017 was TimesSquare Capital Management, an estimated $23.2M sold.

Based on aggregated 13F filings for Q1 2017.